Nano cap Soligenix (NASDAQ:SNGX) jumps 37% premarket on robust volume in reaction to its announcement that it has expanded its collaboration with University of Hawaii at Mānoa to include a potential coronavirus vaccine.
The team has demonstrated the feasibility of
developing heat-stable subunit filovirus vaccines, including Ebola virus
disease caused by the Zaire or Sudan variants. They intend to expand
the technology platform to assess its compatibility with coronaviruses,
including SARS-CoV-2.
https://seekingalpha.com/news/3554150-soligenix-up-37-premarket-on-coronavirus-vaccine-investigation
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.